Where Does the Fat Actually Go? The Biology Behind Cryolipolysis, Explained

Ask ten people who have had a fat-freezing session on their stomach where the fat went, and you will hear ten different answers. It gets urinated out. It melts. It moves somewhere else. Most of these answers are wrong, and the actual biology matters, because it explains the timeline, the limits, and the rare complications of the procedure.

Cryolipolysis, the technology behind controlled cooling devices cleared for abdominal fat reduction, exploits a quirk of adipocytes, the cells that store fat. Fat cells are more sensitive to cold than the skin, nerves, and muscle around them. When a treatment applicator pulls a fold of abdominal tissue between cooling plates and holds it at roughly minus 10 to 4 degrees Celsius for 35 to 60 minutes, the lipids inside adipocytes begin to crystallize. Surrounding tissues, which contain more water and less lipid, tolerate the same temperature without lasting injury.

Here is the critical point: the cold does not destroy the fat cells on the spot. It injures them in a way that triggers apoptosis, often described as programmed cell death. Apoptosis is a slow, orderly shutdown. The cell shrinks, its membrane stays intact, and it signals the immune system to come collect the debris. This is very different from necrosis, the messy, inflammatory cell death you would get from burning or crushing tissue.

Over the following days, an inflammatory response builds in the treated area. Biopsy studies show macrophages, the immune system's cleanup cells, arriving in significant numbers around day three and peaking somewhere between two weeks and one month after treatment. These macrophages engulf the dying adipocytes and their lipid contents piece by piece. The lipids are then processed the same way dietary fat is processed: transported through the lymphatic system, delivered to the liver, and metabolized. Research to date has not shown clinically meaningful spikes in blood cholesterol or triglycerides after treatment, which suggests the clearance happens gradually enough for normal lipid metabolism to absorb it.

This is why results take two to four months to appear. The device does its work in under an hour, but the body's cleanup crew works on its own schedule. Patients who look in the mirror at week two and see no change are not seeing a failed treatment. They are seeing biology mid-process. Most published studies measure outcomes at 12 to 16 weeks, with reported fat layer reductions in the range of 20 to 25 percent per treated area per session, typically confirmed by ultrasound or caliper measurement.

A few common misconceptions deserve direct correction.

Myth one: the fat drains out through the skin or urine as visible fat. No. The lipid is metabolized at the molecular level. Nothing oozes, and urine does not become fatty.

Myth two: the fat comes back in the same cells. Adipocytes cleared by apoptosis and macrophage removal are gone. Adults do not readily generate large numbers of new fat cells in a treated area. However, the remaining fat cells, both in the treated zone and everywhere else, can still enlarge with weight gain. Cryolipolysis reduces the number of fat cells in a region. It does not change how the body stores future calories.

Myth three: it is a weight loss treatment. A treated abdominal area might lose a few hundred grams of fat tissue at most. The scale barely moves. This is a contouring tool for pinchable subcutaneous fat, not a treatment for visceral fat, the deeper fat packed around abdominal organs. Visceral fat sits behind the muscle wall, out of reach of any external applicator, and responds only to diet, exercise, medication, and metabolic health.

The biology also explains the procedure's most discussed complication: paradoxical adipose hyperplasia, or PAH. In a small percentage of patients, instead of shrinking, the treated area gradually enlarges and firms over two to five months, often taking on the shape of the applicator. The mechanism is not fully settled, but the leading hypotheses involve a stimulatory response in surviving fat cells or their precursor cells after sublethal cold injury. PAH does not resolve on its own and typically requires liposuction to correct. Earlier estimates put the incidence near 1 in 4,000 treatment cycles, but more recent reports suggest it may be more common, with some series citing rates closer to 1 in 100 to 1 in 500. Reported risk appears higher in men and in certain applicator types. Anyone considering treatment should ask directly how a provider screens for and manages PAH.

The takeaway is straightforward. Cryolipolysis works through a real, well-documented mechanism: cold-triggered apoptosis followed by slow immune clearance. That mechanism sets honest expectations. Results are gradual, modest, regional, and permanent only in the sense that the removed cells do not return. Understanding the biology is the best defense against both overpromising marketing and underinformed disappointment.

Related reading: Subcutaneous vs. Visceral: Why No Device Can Shrink the Fat Behind Your Abs.